Armata Pharmaceuticals, Inc. PP&E Disclosure
Property and equipment as of December 31, 2024 and 2023 consisted of the following (in thousands):
| December 31, 2024 |
| December 31, 2023 | |||
Laboratory equipment | $ | 21,316 | $ | 19,678 | ||
Furniture and fixtures | 831 | 817 | ||||
Office and computer equipment |
| 438 |
| 438 | ||
Leasehold improvements |
| 3,802 |
| 3,447 | ||
Total | 26,387 | 24,380 | ||||
Less: accumulated depreciation |
| (13,146) |
| (11,821) | ||
Property and equipment, net | $ | 13,241 | $ | 12,559 | ||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Mar 21, 2025 | Showing above |
| 2022 | Mar 16, 2023 | |
| 2016 | Mar 27, 2017 | |
| 2015 | Mar 30, 2016 | |
About PP&E Disclosures
The PP&E disclosure details a company's physical asset base — land, buildings, machinery, and equipment — along with the depreciation methods and useful life assumptions that determine how these costs flow through the income statement. Capitalization policy thresholds reveal management's judgment on the boundary between expense and asset, directly affecting both reported earnings and asset values.
Key signals: changes in estimated useful lives or depreciation methods can materially shift reported earnings without any operational change. Compare capital expenditures against depreciation expense — when capex consistently trails depreciation, the asset base may be aging and underinvested. Watch for large asset impairments or write-downs that signal overvalued carrying amounts. Asset retirement obligations reveal future environmental or decommissioning costs that are often underappreciated. Compare PP&E intensity (PP&E-to-revenue) against industry peers to assess capital efficiency and competitive positioning.